Table 2 Exosomes for clinical management of BCa
From: Exosome, the glass slipper for Cinderella of cancer—bladder cancer?
Country | Age | Molecules | Sensitivity | Specificity | AUC | BCa | |
|---|---|---|---|---|---|---|---|
Iran | BCa:55.84 Healthy:57.4 | ANRIL | 46.67% | 87.5% | 0.7229 | T1/T2 | |
PCAT-1 | 43.33% | 87.5% | 0.7292 | ||||
China | / | TERC | 78.65% | 77.8% | 0.836 | BCa/Healthy | |
Egypt | BCa: 59.5 ± 3.2 | miR-96-5p | 80.4% | 78.4% | 0.85 | BC patients/Healthy | |
miR-183-5p | 91.8% | 81.6% | 0.83 | ||||
miR-96-5p &miR-183-5p | 88.2% | 87.8% | 0.87 | ||||
Egypt | / | Serum exosomes | 82.4% | 100% | 0.97 | BC patients/Healthy | |
Urine exosomes | 92.6% | 83.3% | 0.82 | ||||
China | Training cohort | Validation cohort | mRNA:KLHDC7B CASP14 PRSS1 lncRNA:MIR205HG GAS5 | mRNA:71.9% | 95.2% | 0.88 | BC patients/Healthy |
HCs: 45.7 ± 14.0 | HCs: 47.4 ± 11.3 | lncRNA:67.1% | 87.1% | 0.842 | |||
BCa: 61.4 ± 10.5 | BCa: 64.8 ± 12.5 | Total:88.5% | 83.3% | 0.924 | |||
Japan | / | CEACAM | 81.82% | 97.87% | 0.907 | BC patients/Healthy | |
South Korea | BCa: 66.77 ± 11.56 | Alpha-2-macroglobulin | 93.3% | 34.8% | 0.809 | BC patients/Healthy | |
Healthy donors: 60.35 ± 7.40 | |||||||
China | / | miR-93-5p | 74.1% | 90.2% | 0.838 | BC patients/Healthy | |
miR-516-5p | 72.9% | 89.9% | 0.79 | ||||
Japan | BCa: 72.8 ± 10.6 | SLC2A1 | 0.64 | 0.75 | 0.7 | BC patients/Healthy | |
GPRC5A | 0.54 | 0.72 | 0.64 | ||||
KRT17 | 0.58 | 0.58 | 0.64 | ||||
South Korea | BCa: 66.77 ± 11.56 | Alpha-2-macroglobulin | 93.3% | 34.8% | 0.64 | BC patients/Healthy | |
Healthy donors: 60.35 ± 7.40 | |||||||
Iran | BCa: 62.67 ± 11.96 | TUG-1 | 76.67% | 77.78% | 0.78 | BC patients/Healthy | |
Healthy donors: 57.4 ± 5.7 | |||||||
Japan | / | EphA2 | 61.1% | 97.2% | 0.79 | BC patients/Healthy | |
China | / | H19 | 74.07% | 78.08% | 0.851 | BC patients/Healthy | |
China | / | CA9 | 85.18% | 83.15% | 0.837 | BC patients/Healthy | |
China | BCa: 68.08 ± 10.61 | MYBL2,TK1,UBE2CKRT7,S100A2 | 88.89% | 54.13% | 0.8402 | BC patients/Healthy | |
Healthy donors: 69.89 ± 11.31 | |||||||
Iran | BCa: 55.42 ± 155.55 | UCA1-201,UCA1-203,MALAT1and LINC00355 | 92% | 91.7% | 0.73 | BC patients/Healthy | |
Healthy donors: 68 ± 13.56 | |||||||
Iran | BCa: 61.28 ± 13.01 | MAGE-B4 | 71.7% | 66.7% | 0.67 | BC patients/Healthy | |
Healthy donors: 64.42 ± 15.53 | |||||||
China | / | MALAT1,PCAT-1 and SPRY4-IT1 | 72.1% | 84.6% | 0.844 | BC patients/Healthy | |
China | / | UBC1,PCAT-1 and SNHG16 | 85% | 78% | 0.857 | BC patients/Healthy | |
China | BCa: 67.0 ± 9.8 | PTENP1 | 65.4% | 84.2% | 0.743 | BC patients/Healthy | |
Healthy donors: 66.2 ± 10.7 | |||||||